Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Transfer learning across technologies for ATMPs

Reference number
Coordinator Högskolan i Skövde - Högskolan i Skövde Inst f biovetenskap
Funding from Vinnova SEK 6 740 000
Project duration October 2022 - March 2025
Status Ongoing
Venture AI - Leading and innovation
Call Advanced and innovative AI

Purpose and goal

Advanced Therapy Medical Products (ATMPs), is a field of treatment that is developing very quickly and that is dependent on good quality controls to guarantee the safety and quality of the products. The purpose and goal of the project is to develop an AI-supported platform based on complex RNA sequencing data to be translated into simpler, faster and cheaper analyzes with qPCR in an industrial quality control process.

Expected results and effects

An important parameter in all drug production is quality controls, but for products based on living cells, or parts of cells, these differ from ordinary chemical drugs. In the process of cell production, it is important to know that the genetic information has not been changed or mutated during the process. This project will develop quality systems and with the help of AI streamline large and complex data down to simpler and cheaper analyses in order to be able to produce safe ATMP products in an industrialised way.

Planned approach and implementation

The project have five work packages. WP1 is responsible for general project management, risk management and dissemination. WP2, cultures the human embryonic stem cells that serve as a model product for our platform and generates the sequencing data. In WP3, the data from WP2 will be processed and the AI method will be developed. In WP4, the advanced model trained on complex data will be transfered to a more simple qPCR system. The qPCR systems are developed and validated in WP4. In WP5, the develop systems will be commercialised, including both lab kits and software for data interpretation.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 9 February 2024

Reference number 2022-00923

Page statistics